Analysis of Atrial Fibrillation Treatment Regimes in a Multicenter Cohort of Transcatheter Edge-to-Edge Mitral Valve Repair Patients

Table 1

Clinical characteristics and heart failure medication.

	Total, n = 506	Non-AF, n = 133	Permanent AF, n = 152	Nonpermanent AF, n = 221	value
Age (years)	78.1 ± 7.8	77.4 ± 9.1	79.1 ± 6.9	77.9 ± 7.6	0.2926
Male sex	62.9%	60.9%	71.1%	58.4%	0.012
EuroSCORE II (IQR)	20.0% (23.0)	19.1% (21.9)	20.1% (22.8)	19.6% (23.3)	0.74
STS risk score (IQR)	7.4% (8.8)	7.3% (8.9)	8.5% (10.1)	6.7% (8.5)	0.5924
NYHA class I; NYHA class II; NYHA class III; NYHA class IV	0.2%; 4.7%; 71.0%; 24.1%	0.0%; 5.3%; 73.7%; 21.0%	0.0%; 3.9%; 70.4%; 25.7%	0.5%; 5.0%; 69.6%; 24.9%	0.71
Chronic obstructive pulmonary disease	20.6%	22.6%	23.0%	17.7%	0.5
Coronary artery disease	67.0%	77.4%	64.5%	62.4%	0.0028
Prior cardiac bypass surgery	26.7%	35.3%	25.0%	22.6%	0.0085
Prior percutaneous coronary intervention	55.1%	62.4%	48.7%	55.2%	0.049
Diabetes mellitus	33.4%	35.3%	36.2%	30.3%	0.69
Art. hypertension	80.0%	79.7%	81.6%	79.2%	0.91
Prior stroke	10.9%	11.3%	11.2%	10.4%	0.86
Preexisting ICD	26.9%	26.3%	25.7%	28.1%	0.94
Preexisting CRT	11.7%	11.3%	9.2%	13.6%	0.43
Glomerular filtration rate (mL/min)	47.4 ± 20.2	50.0 ± 22.0	47.9 ± 20.0	45.5 ± 19.2	0.1
NT-pro BNP (ng/L)	2 945.0 ± 4 902.0	2 960.0 ± 5 871.0	2 921.0 ± 4 687.0	2 951.0 ± 4 304.0	0.41
LV function > 45%; LV function 30–44%; LV function < 30%	38.7%; 34.6%; 26.7%	30.1%; 38.3%; 31.6%	44.1%; 33.6%; 22.3%	40.3%; 33.0%; 26.7%	0.053
TR grade III	18.8%	11.3%	29.6%	15.8%	0.0006
Degenerative MR etiology; Functional MR etiology; Combined MR etiology	27.5%; 64.6%; 7.9%	27.1%; 65.4%; 7.5%	26.3%; 65.8%; 7.9%	28.5%; 63.4%; 8.1%	0.96
Heart failure medication
ACE/AT1 inhibitors	74.1%	72.9%	72.4%	76.2%	0.6
ARN inhibitor	7.9%	7.5%	8.6%	7.7%	0.93
Beta blockers	87.9%	87.2%	87.5%	88.7%	0.72
Loop diuretics	89.5%	87.2%	90.8%	90.1%	0.33
Thiazide diuretics	21.3%	21.8%	25.7%	18.1%	0.21
Aldosterone antagonists	48.0%	47.4%	47.4%	48.9%	0.91
Ivabradine	1.4%	3.8%	0.0%	0.9%	0.023
Digitalis	7.7%	0.0%	17.8%	5.4%	<0.0001

Data presented as mean ± SD or median with interquartile range (IQR). AF, atrial fibrillation; ICD, implantable cardioverter defibrillator; CRT, cardiac resynchronization therapy; TR, tricuspid regurgitation; MR, mitral regurgitation; ACE, angiotensin-converting enzyme; AT1, angiotensin II type 1 receptor; ARN, angiotensin receptor neprilysin. p values describe differences between patients without AF and with permanent and nonpermanent AF. The bold values indicate the significance of p values.